{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"7"}],"title":"Increase"},{"measurements":[{"groupId":"OG000","value":"9"}],"title":"No Increase"}],"title":"Day 15"},{"categories":[{"measurements":[{"groupId":"OG000","value":"7"}],"title":"Increase"},{"measurements":[{"groupId":"OG000","value":"9"}],"title":"No Increase"}],"title":"Days 21-28"}],"denoms":[{"counts":[{"groupId":"OG000","value":"16"}],"units":"Participants"}],"description":"To demonstrate that the effector cell infusions result in a clinical effect, phenotypic analyses of blood samples using flow cytometry will be performed prior to, and after each infusion, focusing on the CD8 + populations (CD3+CD8+, CD8+CD56+). As a complement to flow cytometry, the following assays will be used to identify cell subset precursor frequencies, subset proliferation, and cytokine production:\n\n* Dye Dilution Proliferation Assay (DDPA) 36 - Evaluation of CD8+ T Cell Precursors\n* ELISPOT-Quantifying cytokine producing T cells:","groups":[{"description":"Infusing IL-2 and GM-CSF post-HCST\n\nEx-vivo expanded effector cells: This trial will test if the combination of infusing ex vivo expanded cytotoxic effector cells with IL-2 and GM-CSF post-transplant will accelerate immune reconstitution, resulting in an effector cell-versus-myeloma effect and, possibly, improved clinical outcomes.","id":"OG000","title":"Ex-vivo Expanded Effector Cells"}],"paramType":"COUNT_OF_PARTICIPANTS","populationDescription":"Sixteen out of nineteen subject samples were analyzed. Three subject's samples were not available for analysis.","reportingStatus":"POSTED","timeFrame":"Day 15 post-transplant and between days 21 to 28 post-transplant","title":"Count of Participants With Increased CD3+CD8+, CD8+ and CD56+ Concentrations Between Day 15 Post-Transplant and Days 21 to 28 Post-transplant","type":"SECONDARY","unitOfMeasure":"Participants"}